Voices
Rasha Aboelhassan: Should Immunotherapy Be Combined With Anti-Angiogenic Therapy and TACE in HCC?
Rasha Aboelhassan/LinkedIn

Rasha Aboelhassan: Should Immunotherapy Be Combined With Anti-Angiogenic Therapy and TACE in HCC?

Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:

“EMERALD-3 and EMERALD-1  panel discussion

Two clinical trials with different results,

Patients in both EMERALD-1 and EMERALD-3 trials shared the same foundational eligibility: they had unresectable, embolization-eligible hepatocellular carcinoma (HCC).

but in real-world

Should we combine immunotherapy with anti- angiogenic therapy(bevacizumab or Lenvatinib) and with TACE for those patients?

Thanks for panellists who had this challenging discussion:

  • Jens Ricks
  • Joseph P Erinjiri
  • Bruno Sangro”

Rasha Aboelhassan: Should Immunotherapy Be Combined With Anti-Angiogenic Therapy and TACE in HCC?

More posts featuring Rasha Aboelhassan.

Bruno Sangro cancer ESMO GI 2026 ESMOGI26 HCC hepatocellular carcinoma Jens Ricks Joseph P Erinjiri OncoDaily Oncology Rasha Aboelhassan